Reunion Neuroscience Announces Final Closing of its Series A Financing and Plans to Advance RE104 into Clinical Development for the Treatment of Generalized Anxiety Disorder (GAD)

Core Insights - Reunion Neuroscience has successfully closed its Series A financing, raising a total of $133 million, with the final tranche increasing from $21 million to $51 million due to meeting certain efficacy parameters in the RECONNECT study [1][2]. Company Developments - The funds from the Series A financing will fully support the ongoing REKINDLE Phase 2 clinical trial for Adjustment Disorder (AjD) and will also be used to expand the clinical development of RE104 into generalized anxiety disorder (GAD) [2]. - Reunion plans to initiate the RECLAIM Phase 2 clinical trial for RE104 in adults with GAD in the first quarter of 2026 [2][3]. Product Information - RE104 is a proprietary prodrug designed to provide a short, acute psychoactive experience, differing from traditional psychedelics [6]. - The RECLAIM trial will evaluate the safety and efficacy of RE104, with the primary endpoint being the change in Hamilton Anxiety Scale (HAM-A) score from baseline at Week 4 [4]. Market Context - GAD affects approximately 6.8 million adults in the U.S. annually, with current treatment options having significant limitations, leading to a substantial unmet need for effective alternatives [3][4]. - Current treatments for GAD include SSRIs, SNRIs, and psychosocial therapies, but many patients do not respond adequately to these options [3]. Clinical Validation - The RECONNECT study demonstrated clinically meaningful reductions in MADRS scores for postpartum depression, supporting the advancement of RE104 into a Phase 3 trial in 2026 [5]. - The company has received positive feedback from industry experts regarding the potential of RE104 to improve treatment outcomes for patients with limited alternatives [4]. Future Plans - Reunion Neuroscience is also investigating RE104 for additional neuropsychiatric indications, aiming to address significant unmet needs in mental health treatment [7].